Company intelligence / Profile preview
Cirrus Therapeutics
Cambridge, Massachusetts, United Statescirrustx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cirrus Therapeutics is a spinout from the University of Bristol developing a gene therapy targeting a key protein in the eye for the treatment of macular degeneration. The company is focused on advancing this novel approach to address unmet needs in ophthalmology.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Bristol (academic spinout; no major pharma partnerships listed)
Beyond the preview
Go deeper on Cirrus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cirrus Therapeutics.